208 related articles for article (PubMed ID: 23092556)
1. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer.
Chen X; Meng Q; Zhao Y; Liu M; Li D; Yang Y; Sun L; Sui G; Cai L; Dong X
Cancer Lett; 2013 Jan; 328(2):318-24. PubMed ID: 23092556
[TBL] [Abstract][Full Text] [Related]
2. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination.
Suganuma T; Ino K; Shibata K; Kajiyama H; Nagasaka T; Mizutani S; Kikkawa F
Clin Cancer Res; 2005 Apr; 11(7):2686-94. PubMed ID: 15814650
[TBL] [Abstract][Full Text] [Related]
3. Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway.
Fan F; Tian C; Tao L; Wu H; Liu Z; Shen C; Jiang G; Lu Y
Biomed Pharmacother; 2016 Oct; 83():704-711. PubMed ID: 27470571
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis.
Oh E; Kim JY; Cho Y; An H; Lee N; Jo H; Ban C; Seo JH
Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1071-81. PubMed ID: 26975580
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the renin-angiotensin system downregulates tissue factor and vascular endothelial growth factor in human breast carcinoma cells.
Napoleone E; Cutrone A; Cugino D; Amore C; Di Santo A; Iacoviello L; de Gaetano G; Donati MB; Lorenzet R
Thromb Res; 2012 Jun; 129(6):736-42. PubMed ID: 22188725
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer.
Kosaka T; Miyajima A; Takayama E; Kikuchi E; Nakashima J; Ohigashi T; Asano T; Sakamoto M; Okita H; Murai M; Hayakawa M
Prostate; 2007 Jan; 67(1):41-9. PubMed ID: 17044086
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer.
Kosugi M; Miyajima A; Kikuchi E; Horiguchi Y; Murai M
Clin Cancer Res; 2006 May; 12(9):2888-93. PubMed ID: 16675585
[TBL] [Abstract][Full Text] [Related]
9. Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma.
Arafat HA; Gong Q; Chipitsyna G; Rizvi A; Saa CT; Yeo CJ
J Am Coll Surg; 2007 May; 204(5):996-1005; discussion 1005-6. PubMed ID: 17481528
[TBL] [Abstract][Full Text] [Related]
10. Aspirin downregulates angiotensin type 1 receptor transcription implications in capillary formation from endothelial cells.
Mitra S; Wang X; Khaidakov M; Ding Z; Ayyadevera S; Hearnsberger E; Goyal T; Mehta JL
J Cardiovasc Pharmacol; 2012 Aug; 60(2):187-92. PubMed ID: 22561363
[TBL] [Abstract][Full Text] [Related]
11. Novel hexahydrocannabinol analogs as potential anti-cancer agents inhibit cell proliferation and tumor angiogenesis.
Thapa D; Lee JS; Heo SW; Lee YR; Kang KW; Kwak MK; Choi HG; Kim JA
Eur J Pharmacol; 2011 Jan; 650(1):64-71. PubMed ID: 20950604
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase/Akt pathway.
Zhao Y; Chen X; Cai L; Yang Y; Sui G; Fu S
J Cell Physiol; 2010 Oct; 225(1):168-73. PubMed ID: 20458733
[TBL] [Abstract][Full Text] [Related]
14. Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells.
Wang L; Wang Y; Du H; Jiang Y; Tang Z; Liu H; Xiang H; Xiao H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1247-57. PubMed ID: 26464351
[TBL] [Abstract][Full Text] [Related]
15. [Inhibition of bladder cancer cell growth and angiogenesis by co-blockage of vascular endothelial growth factor and its receptor KDR].
Chen XL; Liu LC; Xu ZG; Li Z; Li RW; Gao RJ; Wang S; Zhang M; Guo H
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):578-82. PubMed ID: 19102933
[TBL] [Abstract][Full Text] [Related]
16. Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: implications for tumor angiogenesis.
García-Quiroz J; Rivas-Suárez M; García-Becerra R; Barrera D; Martínez-Reza I; Ordaz-Rosado D; Santos-Martinez N; Villanueva O; Santos-Cuevas CL; Avila E; Gamboa-Domínguez A; Halhali A; Larrea F; Díaz L
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():215-22. PubMed ID: 24120914
[TBL] [Abstract][Full Text] [Related]
17. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth.
Fujita M; Hayashi I; Yamashina S; Fukamizu A; Itoman M; Majima M
Carcinogenesis; 2005 Feb; 26(2):271-9. PubMed ID: 15637093
[TBL] [Abstract][Full Text] [Related]
19. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
20. Valsartan inhibits NPC cell line CNE-2 proliferation and invasion and promotes its sensitivity to radiation.
Wang Q; Zhao W; Wu G
Eur J Cancer Prev; 2009 Nov; 18(6):510-7. PubMed ID: 19687742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
